BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 22, 2026
Home » Authors » Mark McCarty

Mark McCarty

Articles

ARTICLES

Washington roundup: Industry weighs in on CMS's doctor payment sunshine rule

Feb. 22, 2012
By Mark McCarty

FDA advisory committees: Is there a problem?

Feb. 21, 2012
By Mark McCarty
I've attended more FDA advisory committee hearings than most and believe I have a decent grasp of how those hearings should go. It's true I'm no expert, but recent hearings for medical devices have gone in a direction that strikes me as odd. For instance, at the Jan. 11 meeting of the gastroenterology/urology devices committee, FDA's Herb Lerner, MD, addressed post-market study requirements for an application filed by Torax Medical of St. Paul, Minnesota. Among the items of discussion that day were quality-of-life scores for gastroesophageal reflux and measures of esophageal pH. Lerner said: “This is a very interesting...
Read More

Washington roundup: Provider says artificial feet more often underprescribed

Feb. 21, 2012
By Mark McCarty

Washington roundup: Special Counsel widens probe into FDA's e-mail monitoring

Feb. 17, 2012
By Mark McCarty

Washington roundup: Shuren says dumping 510(k) determination right for de novo

Feb. 16, 2012
By Mark McCarty

Washington roundup: $595M user fee agreement will measure by total review times

Feb. 15, 2012
By Mark McCarty

Washington roundup: 2013 budget proposal blasted over Medicare, CDRH funding

Feb. 15, 2012
By Mark McCarty
The Obama administration has published its budget proposal for fiscal year 2013 and the proposal includes a drop in appropriated funds of $4 million for FDA's Center for Devices and Radiological Health. As expected, the budget also calls for cuts to Medicare that could have an effect on makers of imaging equipment and durable medical equipment as well, giving device makers an incentive to turn out in force on Capitol Hill to blunt the damage in any spending bills Congress might draft.
Read More

FDA advisory committee: Panel sees class III for CES, doc says vets need treatment

Feb. 14, 2012
By Mark McCarty

Washington roundup: IRS publishes device tax rule, but industry hammers at tax

Feb. 13, 2012
By Mark McCarty

Ditching Medicare: Maybe crazy, but tougher than you think

Feb. 12, 2012
By Mark McCarty
There are many definitions for the word “crazy,” and here's another. Crazy is when you want to get out of Medicare and save the government and the taxpayer money, but the government won't let you. Recent reports indicate that a group of five senior citizens, including former Texas Republican congressman Dick Armey, are okay with their Social Security benefits, but that the law is forcing them to enroll in Medicare Part A if they want to stay on Social Security. The case made it to the Court of Appeals for the District...
Read More
View All Articles by Mark McCarty

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 21, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing